You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨康希諾生物(6185.HK)午後漲幅擴大至8.58% 再創歷史新高
格隆匯 12-30 14:30
格隆匯12月30日丨康希諾生物(6185.HK)今日股價再次拉昇創新高,現大漲8.58%,報62港元,暫成交1836萬港元,最新總市值138億港元。近期股價強勢,持續累漲創新高,自11月中旬以來累漲75%。本月中旬康希諾生物-B(06185.HK)四價腦膜炎球菌結合疫苗新藥註冊申請獲藥品審評中心納入優先審評。光大證券點評稱,公司MCV4報產納入優先審評,國內首個流腦創新疫苗收穫曙光,維持“買入”評級。分析稱首款產品MCV2 疫苗有望於2020年上市,重磅產品MCV4有望於2021年起貢獻業績。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account